Sravya Nakka

Postdoctoral Associate (2023-present). Infection biologist by training with a Ph.D. in Biomedical Sciences from Orebro University, Sweden. Currently involved in studies focused on high containment level emerging pathogens. Prior experience in phase I/II/III human vaccine clinical trials (Ebola, Shigella/ETEC), preclinical vaccine studies (COVID, HSV-2, HIV-1) and in vitro studies focused on immunomodulatory effects during host-pathogen interactions (S. aureus, P. gingivalis and S. enterica).